On the heels of its financing and clinical plans, the rebranded entity previously launched as Onco3R Therapeutics is now operating as Coultreon Biopharma, according to reporting on the $125 million Series A. The update ties the corporate rebranding to the company’s intent to develop an immunology “pipeline-in-a-pill” program sourced from Galapagos. The rebrand clarifies the company’s positioning: advancing former Galapagos immune drug candidates through oral small-molecule development rather than injectable biologic pathways. Investors will continue to track whether Coultreon can translate differentiation claims into Phase 2 response and durability. For the market, the timing underscores how quickly asset carriers can pivot from restructuring to clinical execution after financing and target confirmation.